INTRODUCTION
Some national health organizations advocate screening entire communities for pediatric asthma. They do so for the following reasons: asthma is associated with an early childhood onset; it is one of the most common chronic diseases in children; it is a common reason for school absences, which are a factor in poor school performance; and it is the leading cause of hospitalization in childhood (1-5). In addition, some children are undiagnosed and many are undertreated (6) (7) (8) (9) (10) (11) . Much of the morbidity associated with asthma is largely preventable with proper treatment (12) ; therefore, the desire to implement asthma screening in the population is quite natural. Although population screenings for asthma make sense in theory, recent analyses of existing asthma screening methods and health outcomes concluded that the benefits of populationbased asthma screening are unproven (13, 14) . Despite the lack of clear evidence of benefit, some organizations continue their advocacy of population-based asthma screening (15) (16) (17) (18) (19) . In 2005, the Behavioral Science and Pediatric Assemblies of the American Thoracic Society convened a multidisciplinary panel of experts to review the existing literature and to attempt to answer the question of whether population-based asthma screening programs for children are warranted at this time. Before the workshop, participants were assigned topics for which they reviewed the literature and prepared presentations. Topics included the following: (1 ) a review of the World Health Organization criteria for population-based screening (see Table 1 ), (2 ) experiences with the International Study of Asthma and Allergies in Childhood (ISAAC) questionnaire, (3 ) experiences with several National Heart, Lung, and Blood Institute (NHLBI)-funded school-based asthma screening studies, (4 ) experience with asthma screening/case detection in Europe, (5 ) the Breathmobile experience, and (6 ) the experiences of one of the American College of Asthma, Allergy, and Immunology-funded school-based asthma screening study sites. Additional topics presented addressed the impact of false positives and false negatives, and where asthma might fit into the continuum of childhood chronic diseases that may benefit from screening/case detection. After the presentations, much discussion ensued, and opinions/ recommendations were formulated based on group consensus. The methodology for the literature review was left to each presenter's discretion; additional evidence from the literature was offered in the discussion. After the meeting, the participants were invited to submit their findings in writing to the organizers. Each participant had an opportunity to review and comment on the symposium proceedings before submission of the document. This document summarizes the group's findings and recommendations.
PROCEEDINGS
Participants began the workshop by carefully reviewing the terminology used to describe the process of identifying children with asthma. "Screening" refers to a process used to identify individuals with disease but who are in a preclinical (asymptomatic) state. In contrast, "case detection" identifies individuals with disease who are symptomatic but undiagnosed. Therefore, the term case detection most accurately describes the methods that are currently used and advocated in the asthma screening literature (13) . Even though the term case detection best describes current methods, this semantic argument should not overshadow the most important, underlying question: whether asthma screening or case detection is advisable at this time.
The current state of the art for asthma case detection and its relevant outcomes were evaluated by workshop participants using the World Health Organization's criteria (see Table 1 ) for scientifically acceptable population-based screening (13) . This document presents the findings of the group as they relate to each of these criteria.
THE CONDITION MUST BE AN IMPORTANT HEALTH PROBLEM
The high prevalence of asthma and the cost of disease to society clearly attest to its importance as a public health problem. Studies indicate that the prevalence of undiagnosed asthma in children ranges from 3 to 20% (6, (20) (21) (22) (23) . Furthermore, the prevalence of undertreatment in persistent asthma is high (8) (9) (10) (11) (24) (25) (26) . Certain high-risk subgroups within the population may have even higher rates of undiagnosed and undertreated asthma and therefore may benefit more from case detection programs (see section 8). Before undertaking asthma case detection, it is important to estimate the prevalence of undiagnosed and/or undertreated asthma in the targeted population. This panel acknowledges that childhood asthma is an important health condition; however, the panel cannot unequivocally recommend implementation of widespread population-based asthma case detection programs. Although there is evidence to suggest that case detection programs may be beneficial in settings with a high prevalence of undiagnosed and/or undertreated asthma (27) , such programs should be weighed against expenditures for other programs that also provide important public health benefits. Even if one were to identify a case of undertreated asthma, there is no certainty that the patient would then have access to and/or receive optimal therapy (see section 4).
Bottom line: Although asthma is an important public health problem, the probability of undiagnosed and/or undertreated asthma in the target population should be sufficiently great to justify the expense.
THE NATURAL HISTORY OF THE DISEASE STATE SHOULD BE UNDERSTOOD
Asthma likely consists of multiple phenotypes, each with its own unique natural history (1, 4, 28). However, reliable markers to fully differentiate among the phenotypes are not clinically available. In addition, the current state of medical practice is unable to identify children who are in a preclinical stage. It is also unclear whether early intervention in a preclinical stage would improve the natural history of the disease. Even in patients with known asthma, the nature of progression, if any, in mild, moderate, and severe asthma is not clear. It is also unknown whether treatment can reverse progression of the disease (29) (30) (31) (32) . In toddlers with a history of wheezing, fluticasone propionate, although controlling symptoms, does not alter the course of asthma (33) . Thus, it appears that even beginning treatment at age 2 or 3 years is too late to alter the course of asthma. If early intervention could improve the natural history of asthma, it is possible that case detection would need to occur in very early life, because it appears that many of the asthma phenotypes are likely to be firmly established by the time children are schoolaged. An exception to this may be found in asthma phenotypes that first express themselves during adolescence (34) . It is at least reassuring to know, however, that inhaled steroids can control disease even in toddlers; thus, even though the treatment does not alter the natural history of asthma, one could argue for case detection even in that age group to potentially reduce morbidity from the disease.
Bottom line: No evidence exists that early intervention with treatments currently available alters the natural history of asthma.
THERE SHOULD BE A RECOGNIZABLE LATENT OR EARLY SYMPTOMATIC STAGE
Because a latent (preclinical) phase of asthma has not been identified and no biomarkers exist to reliably identify asymptomatic patients, classic screening per se is not possible. Furthermore, even when asthmalike symptoms appear for the first time, particularly in infancy, they do not reliably predict a future asthma diagnosis (5) . The same problems exist with clinical tools that have been developed to identify asthma in toddlers with recurrent wheezing (35, 36) ; it is not possible to accurately identify prospectively which toddlers will develop asthma. Furthermore, the definition of "early symptomatic stage" in asthma is unclear; one may have had symptoms for many years without realizing their significance. Trials of aggressive allergen avoidance in early life have yielded modest reductions in some asthma symptoms in toddlers (37, 38) and school-aged children (39, 40) . Cetirizine treatment of infants with atopic dermatitis who were sensitized to house dust mite or grass pollen has been associated with reduced risk of developing asthma (41) . Other potential risk factors for asthma development include obesity and viral illnesses; to date, no clinical trials have been performed to document that avoidance of these conditions can alter the natural history of asthma onset. Thus, we have no clear-cut mechanism to reliably identify presymptomatic individuals with asthma. Efforts to reduce asthma onset in "high risk" children have yielded at best modest results for very high cost, and potentially impacted only on those with an atopic phenotype. However, when programs are viewed from the case detection perspective, the criterion that a preclinical phase must exist does not necessarily apply.
Bottom line: No preclinical state for asthma has been reliably identified. . Unfortunately, even with these guidelines, undertreatment of asthma is a common problem (8, (24) (25) (26) 42) ; therefore, the benefit of case detection programs will be partially offset by difficulty in obtaining effective treatment for those children identified. This problem may be most pronounced in the very populations in which case detection would be most beneficial (vulnerable populations with high prevalence of undiagnosed asthma). Lessons learned from several asthma intervention programs suggest that it is difficult to engage primary care physicians to improve the quality of asthma care (22, 26, 43) . However, another study providing intensive asthma education for physicians and allied health staff in a public health department setting demonstrated modest improvements in the provision of asthma education and the prescription of asthma controller medications for patients with persistent asthma (44) (45) (46) . The feasibility of reproducing these programs for all or even most primary care physicians is unknown.
THERE SHOULD BE ACCEPTED TREATMENT FOR
Bottom line: Although accepted treatments for asthma exist, undertreatment is still common; therefore, additional work is needed before this criterion is met.
FACILITIES FOR DIAGNOSIS AND TREATMENT SHOULD BE AVAILABLE
Case detection for any disease without assured access to followup diagnostic and treatment services makes it unlikely that improved health outcomes will result from the activity. Current evidence suggests that identifying and referring patients with probable asthma to a health care provider is insufficient to improve rates of appropriate asthma care. One recent study, conducted in a relatively affluent community with adequate physician coverage, demonstrated that less than one-third of children who were referred to care after being identified with undertreated asthma were actually seen by a physician (26) . Other studies have attempted to overcome this problem by locating health care providers within or very near the schools themselves or by transporting the children to the health care providers (47) (48) (49) (50) (51) (52) (53) (54) (55) . Although these options may be effective in improving care, they are not currently available in a majority of schools or communities and require significant resources to establish and maintain. Another limitation of some of these approaches is that medical care should be available on a consistent basis, not just limited to a one-time visit to confirm a diagnosis or "tune up" care. Ideally, medical care would also include access to asthma specialists who can provide comanagement for children with moderate to severe asthma. It must be noted that, even in areas where reliable follow-up care is readily available, it is unclear whether these providers can handle a rapid influx of large numbers of children who may need to be evaluated for possible asthma as a result of population-based case detection programs. Until these shortcomings can be addressed, the potential positive impact of population-based case detection programs cannot be fully realized. For this reason, case detection programs should not be implemented in communities where reliable linkages to appropriate asthma care are unavailable.
Bottom line: Many communities lack facilities where reliable follow-up asthma care is readily available for those who are identified with the disease.
THERE SHOULD BE A SUITABLE SCREENING TEST OR EXAMINATION
Before the adoption of a specific tool for identifying asthma in a given population, the key stakeholders should carefully consider the primary purpose of the intervention (i.e., identifying undiagnosed children vs. undertreated children, or both) and should identify a tool that will be valid in the population of interest. Most asthma case detection in children has been performed at public schools; however, children who attend private school, who are home schooled, or who are absent on the day of case detection activities can be missed. In a study in a relatively affluent community that included private schools, the response rate for the initial surveys was higher than in those studies that only included public schools; however, the follow-up rates did not differ (26) . Furthermore, asthma may not be considered a priority by all school systems. Schools should be viewed as equal partners with full buy-in if school-based case detection programs are to be successful in the long run. Finally, no case detection technique is perfect; ultimately, a health care provider should be available to confirm or refute the diagnosis, and to provide appropriate care for the child who is identified with the disease.
There is no existing instrument that can reliably identify presymptomatic children with asthma. Therefore, existing surveys are case detection instruments (to identify symptomatic children) that are based on the diagnostic criteria set by the National Asthma Education and Prevention Program (NAEPP [the NHLBI-EPR2 guidelines]), GINA, and others. These surveys generally include 2 to 16 questions presented to parents, but some are also presented to children who are able to report their own symptoms (56) . Published reports of some of these instruments' performance are provided in Table 2 . These instruments are not directly comparable in that they were tested in different populations and used different gold standards for the validation procedure.
When evaluating the accuracy of these instruments, consideration should be given to the interaction between prevalence and positive predictive value. A diagnostic tool's positive predictive value is increased in high-prevalence settings and decreased in low-prevalence settings. The studies in Table 2 were conducted in populations where the asthma prevalence ranged from 25 to 50%. Therefore, one would predict that these instruments would not perform as well when used in the general population where asthma prevalence is lower (57) . The differences observed in performance of the various instruments relate in part to the combination of items used to define a positive screen. Case detection instruments that are most likely to be valuable are those that are brief with high sensitivity and specificity.
Other important issues impact on the feasibility and reliability of survey methodology for population-based case detection. Certainly, the availability of adequate financial resources is critical. In addition, case detection may impact classroom time if surveys are conducted with children or children perform pulmonary function as part of the case detection program. The age of the child dictates whether surveys should be sent only to parents versus relying on self-reporting by children in the classroom to narrow the focus of parental survey or further evaluation. The most widely used survey to assess asthma prevalence has been the ISAAC questionnaire, which is available in print and video formats (58) (59) (60) . The ISAAC has had multiple translations and its items are designed to be given across cultures. Concordance between the written and video ISAAC survey tools has been modest and criteria for how many scenes a child must identify to be considered a positive responder to the video tool have varied among studies. In addition, ISAAC is designed to measure prevalence of asthma and allergy symptoms, not to detect individuals in need of treatment.
Because asthma is a disease characterized by episodes of airflow obstruction that are often reversible (NAEPP definition, 1997), objective measures of lung function and bronchial hyperresponsiveness (BHR) are commonly included in case detection programs. These measures have been used to confirm positive survey responses, thereby reducing false positives. Detection of obstruction during baseline lung function testing is frequently assessed by measuring peak flow or by obtaining spirometry. When obstruction is present, a 12% response of peak flow or 
THE SCREENING TEST SHOULD BE ACCEPTABLE TO THE POPULATION
Available evidence suggests that existing case detection methods involving questionnaires, physiologic testing, or both are likely to be acceptable to the general population. High questionnaire return rates (75-98%) documented in most population-based studies suggest that asthma questionnaires are widely acceptable to the population. However, many studies suggest that it is necessary to provide incentives to obtain high response rates; this practice greatly increases the cost of asthma case detection programs. One program reported that over three-quarters of parents in an inner-city elementary school system consented to physiologic testing of their children (78-84% consenting to spirometry and a modified exercise challenge [57] ); thus, these tests would likely be acceptable to the population at large. As newer algorithms and tests become available, their acceptability will have to be assessed.
Bottom line: Tests likely to be used for case detection appear to be acceptable to the population.
THE COST OF SCREENING (INCLUDING DIAGNOSIS AND TREATMENT) SHOULD BE ECONOMICALLY BALANCED Targeting Those for Case Detection to Maximize Economic Balance
Because population-based case detection is expensive, there should be convincing evidence that children identified with asthma by case detection benefit as a result of having been recognized. For asthma case detection to be cost-effective, asthma should cause considerable morbidity in the population being examined and the population should contain a sufficiently large number of individuals who are undiagnosed or whose asthma is not well controlled (to maximize the positive predictive value as discussed earlier). In a population that contains a sufficiently large number of undiagnosed individuals, it is also important to consider how disease severity is distributed among those undiagnosed and whether or not identifying children will result in their accessing care. Some recent studies have indicated that children with undiagnosed asthma have less severe asthma than those who have a current diagnosis (22, 57) , whereas others have found a high prevalence of persistent disease among the undiagnosed. Researchers have also demonstrated significant symptoms among those diagnosed with persistent disease (25, 63, 64) . In fact, a recent study in Arkansas indicated that 98% of students with asthma were identified by parent-reported physician diagnosis of asthma alone, indicating a low prevalence of undiagnosed disease in that community (64) . Furthermore, those with a current asthma diagnosis had greater morbidity than those without a current diagnosis. Thus, in some areas, children with significant symptoms may have already sought care. If this is true, then case detection may only identify children with mild asthma for whom treatment, while perhaps benefiting the individual, may have little public health impact. Furthermore, simply identifying children with asthma may not improve health outcomes (7), given that they may or may not receive further evaluation and care for their newly identified disease (26) . This is at least partly explained by the fact that many of the children identified will never come to the attention of their health care provider or the formal medical system. The possibility that case detection may only identify those with mild asthma and may not result in improved care for children identified suggests that the decision to perform case detection should be considered in the context of how available resources might be better used to improve other competing health problems.
It is likely that those groups experiencing the greatest morbidity and mortality would benefit most from case detection programs. Morbidity and mortality from asthma disproportionately affect low-income minority communities (65) . Asthma exacerbation prevalence is highest in children aged 5 to 14 years and in African Americans (65). Bloomberg and colleagues found hospital readmissions for childhood asthma to be more common in African Americans who were either self-paying or who had Medicaid insurance; prior admission was the most specific predictor of subsequent admission (66) . Conversely, whites may be at greater risk for asthma death during sports; individuals with even mild disease may be at risk as well (67, 68) . In addition, a review of 51 pediatric asthma deaths over a 3-year period beginning May 1, 1986, in Victoria, Australia, demonstrated that onethird of these deaths occurred in individuals who had a previous history of mild asthma (69) . One study found that children with asthma have 1.7 times the risk of having a learning disability, and children with asthma from families with incomes below $20,000 had twice the odds of grade failure (3). However, in the overwhelmingly white, relatively affluent school system of Rochester, Minnesota, asthma had no impact on school performance (70) . Furthermore, in a cohort of relatively affluent children with mild or moderate asthma, the disease did not impact on neurocognitive functioning (71) .
The data are insufficient to conclusively identify those who would most benefit from asthma case detection. It would appear that, when considering morbidity factors, inner-city, low-income minority children in elementary or junior high school should be targeted, because this is the group in which some benefit to case identification has been identified (27) . However, children in these areas are those most likely to have limited access to appropriate care, and the primary problem limiting the impact, to date, of case detection programs on asthma outcomes has been the lack of reliable follow-up medical care. Thus, the workshop participants believe that the current priority goal should be to identify children with moderate to severe persistent asthma who are either undiagnosed or those who are diagnosed but are still experiencing significant symptoms, when linkage to appropriate care can be assured. Furthermore, given the risk of death to those with asthma who participate in sports, carefully looking for asthma in preparticipation physical examinations is important. In settings where access to reliable follow-up care and resources to implement programs are available, case detection programs may have benefit, especially given the observation that earlier treatment of asthma in children (72) and adults (73) is associated with higher lung function. Again, the costs should be carefully weighed against competing public health needs.
Impact of False Positives
Before considering instituting universal asthma case detection programs, the risk of false positives should be considered. False positives as a result of asthma case detection programs can be stressful for families and overburden health care providers with unnecessary referrals. Even though positive evaluations do not always (or even usually) equate to diagnoses of asthma, the confusion and concern they engender are significant. Therefore, false-positive evaluations need to be minimized. When case detection is done in a multistage process, the number of false positives is reduced, but cost and impact on the school system increase, so there is a trade-off (21) . Furthermore, as mentioned above, targeting populations with expected high disease prevalence can reduce the number of false positives identified by a case detection procedure.
Impact of False Negatives
In addition to false positives, screening or case detection programs run the risk of false negatives. Most case detection procedures have had high sensitivity, with few false negatives. In a recent validation study of a multistage case detection procedure, the false-negative rate varied from 3.3 to 18% depending on the questionnaire that was used (57) . Roughly half of the false negatives represented children with mild intermittent asthma, with the remainder divided almost evenly between mild and moderate persistent asthma (57) . Continuous screening or case detection could potentially reduce the likelihood of false negatives; further studies are needed to assess this.
Cost/Benefit
In considering the costs versus the benefits of a case detection procedure, one should consider the outcomes shown in Figure 1 . Table 3 presents a list of direct and indirect costs that workshop participants identified as associated with asthma case detection programs. The costs of a case detection program include the costs of the program itself such as school staff time, student time away from class, health care provider time, additional correspondence, and records; the costs of evaluation of those who test positive; the costs of treatment for those who are diagnosed; and the costs of false negatives. The costs of health care in treated and untreated individuals include preventive care for those treated (medications, visits, peak flow meters, spacers, transportation to/from visits, time off work/school) and adverse health outcomes in those who are treated and untreated.
In considering costs, one should also consider the opportunity costs, or the forgone opportunities, when resources are used to support a particular decision. For example, resources that are spent on identifying children with undiagnosed asthma are resources that are not available for treatment of the disease or for identification of other diseases or conditions. In addition, the costs and benefits may differ by disease severity.
TABLE 3. COSTS ASSOCIATED WITH SCHOOL-BASED CASE DETECTION
Cost for Testing • Preparation for case detection: determine who, how, etc.
-Determining whether to screen or detect probable cases and which method to use Spirometry with or without exercise testing Questionnaire
• In conclusion, to determine the cost-effectiveness of a case detection procedure, we should consider who we are finding, how much it costs to find them, and what the implications are for health outcomes of those who are found as well as the implications for those who are not found. To date, no studies examining the cost-effectiveness of asthma case detection programs have been conducted.
Health and Functional Outcomes
Studies of case detection programs should provide evidence of patient outcomes that are important enough to the individual patients or to public health to justify the expenditures involved in time and opportunity, and social costs. Neonatal screening for cystic fibrosis coupled with aggressive medical management from the time of diagnosis has been associated with improved nutritional status and long-term growth (74) , reduced acquisition of Pseudomonas aeruginosa, and improved survival (75) . In asthma, there is reason to believe that a combination of early and accurate diagnosis, and suitable management and appropriate monitoring, could result in positive health outcomes by preventing the serious physical and psychosocial morbidity and mortality related to asthma. To date, mixed health outcomes have been documented following case detection activities in schools, ranging from modest improvements in functional status (25, 27, 49) to no changes in health status (7, 26) . However, it is important to recognize that it is not the case detection activities per se that improve the asthma outcomes but rather the intervention activities within these programs, just as is the case with neonatal screening for cystic fibrosis. Table 4 lists outcome measures that workshop participants believe should be considered for future evaluation of case detection procedures. These range from individual-level to populationbased outcomes. At the outset, it is appropriate and prudent to measure process outcomes (examples include the number of students with asthma who receive education on the disease, or number of students participating in case detection programs) as these assess the effectiveness of program implementation. Ultimately, however, effective implementation of interventions should result in change that can be measured with impact/ outcome measures, including adoption of policies or legislation as well as health, quality of life, and school performance improvements. Thus, although process outcomes are important to measure at the outset, the effectiveness of any case detection program should ultimately be assessed by measures of reduction in disease morbidity, at the individual and the population levels.
Bottom line: There are insufficient data to state whether or not asthma case detection is economically balanced.
SCREENING SHOULD BE CONTINUOUS
Each year, new children join the ranks of school-aged and children who previously had no signs or symptoms of asthma identifiable by case detection questionnaires develop asthma. Therefore, case detection cannot be a one-time event.
Bottom line: Once appropriate case detection methods are identified, further studies will be required to assess the appropriate frequency for continued case detection.
SUMMARY
The workshop participants concluded that, at this time, the adoption of population-based asthma case detection programs is unwarranted given the lack of evidence of improvement in health outcomes as a result of case detection. It is important to note, however, that there are advocates for nationwide asthma screenings. One such ongoing effort is sponsored by the American College of Allergy, Asthma, and Immunology; on their website, the chair of their screening effort states, "We believe the nationwide screenings help raise awareness about asthma and the fact that the disease doesn't have to lead to major lifestyle compromises. By informing people about the symptoms of asthma and by offering free screenings and consultation by an allergist, we can help improve quality of life for children and adults with asthma" (http://www.acaai.org/public/lifeQuality/nasp/nasp.htm, accessed August 15, 2006) . The actual health outcomes of these screenings, however, are unclear. Although such voluntary programs in community settings may have value, the external validity of their outcomes is limited by self-selection of the individuals choosing to be screened.
The participants of this workshop believe that limited case detection programs may be appropriate in areas where there is a high prevalence of undiagnosed asthma and where newly identified patients have functional access to consistent, highquality asthma care. Methods to identify children with significant asthma symptoms may also be appropriate. The use of case detection methods to identify children with undiagnosed asthma may be a worthy future goal. However, before this panel can recommend widescale case detection, a number of issues should be addressed:
1. Health care systems should be adapted to deliver care that optimizes health outcomes in populations that are difficult to reach through our traditional health care delivery mechanisms. The goal is to guarantee timely access to asthma care consistent with existing guidelines and access to education to improve daily self-management. Access to health behavior experts and social workers will be important to address psychosocial and health literacy issues which impact on adherence and health outcomes. 2. The primary site of asthma case detection should be the primary care clinician's office. Clinicians should be attentive to respiratory symptoms and reports of morbidity or missed school days among children. If populations are identified that are not reached by primary care, then alternative methods should be developed for other sites (possibly schools, community centers, or youth-serving organizations). In some settings, it may be prudent to combine asthma case detection with other case detection procedures that identify other common, chronic diseases, such as vision screening for myopia. 3. Tools should be refined to identify those who would benefit most from further assessment and treatment for undiagnosed and/or undertreated asthma. 4. Identification of a preclinical state for asthma may allow for true screening and treatment to prevent the onset of the disease. A better understanding of the different asthma phenotypes and their natural history is needed to help inform the nature, timing, and possibly the setting of ideal asthma case detection or screening programs. 5. The cost-effectiveness of asthma case detection programs should be examined.
Until these issues are addressed, parents, school personnel, and primary health care providers should be attentive to respiratory symptoms in children. Given that public health resources within communities and schools are very limited, current efforts should seek to identify and intervene with those children who are experiencing significant morbidity from respiratory symptoms. This targeted use of resources should include connection to proper medical care to have an impact on asthma morbidity. This ATS workshop report was developed by an ad hoc subcommittee of the ATS Behavioral Science and the Pediatrics Assemblies.
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